Physician profile
Robert K Anderson
NPI 1134280407
$1,272.04
in general payments reported to CMS, 2019-2025
22 companies · $72.93 in 2025
The $72.93 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $128 · 2020: $11.77 · 2021: $200 · 2022: $170 · 2023: $438 · 2024: $251 · 2025: $72.93.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $762.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $762.41 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $343.36 | 2021-2024 | Rybelsus, Ozempic |
| Abbvie INC. | $196.31 | 2020-2024 | Ubrelvy |
| Amgen INC. | $164.05 | 2021-2024 | Prolia, Evenity |
| Lilly USA, LLC | $70.58 | 2022-2024 | Mounjaro, Zepbound, Jardiance |
| Janssen Pharmaceuticals, INC | $62.32 | 2019 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.56 | 2019-2024 | |
| Glaxosmithkline, LLC. | $43.00 | 2023-2024 | Shingrix, Arexvy, Trelegy Ellipta |
| E.R. Squibb & Sons, L.L.C. | $38.18 | 2025 | Eliquis |
| Alexion Pharmaceuticals, INC. | $34.75 | 2025 | Ultomiris |
| Pfizer INC. | $34.14 | 2021-2022 | |
| Astrazeneca Pharmaceuticals LP | $29.95 | 2019-2023 | Farxiga |
| Novartis Pharmaceuticals Corporation | $28.71 | 2023 | |
| Sanofi Pasteur INC. | $25.18 | 2023 | |
| Amarin Pharma, INC. | $25.02 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $20.78 | 2021 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $19.28 | 2022 | |
| Shield Therapeutics INC | $14.46 | 2023 | Accrufer |
| Boston Scientific Corporation | $13.78 | 2023 | Watchman |
| Nabriva Therapeutics, Plc | $12.70 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $11.80 | 2019 | |
| Arbor Pharmaceuticals, INC. | $11.17 | 2021 | |
| Tactile Systems Technology INC | $10.96 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Anderson listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.